Cointime

Aro Biotherapeutics

company

About

Aro Biotherapeutics is a biotechnology company pioneering the development of tissue-targeted genetic medicines.

  • 1 - 10

Highlights

Total Funding Amount
$88M
Funding Rounds
1
Investors
1

Details

Last Funding Type
Series A
Last Funding Money Raised
$88M
Industries
Biotechnology,Health Care,Medical,Pharmaceutical,Therapeutics
Founded date
Jan 1, 2017
Number Of Employee
1 - 10
Operating Status
Active

Aro Biotherapeutics is focused on the development of a new protein drug platform called Centyrins, designed to achieve better efficacy and safety profiles for patients with cancer and other serious diseases. Centyrins are small, non-antibody protein scaffolds that can be expressed as multi-specifics with novel therapeutic mechanisms of action. Centyrins are also ideal for the targeted delivery of complex drug payloads, including nucleic acids.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$88M
Aro Biotherapeutics has raised a total of $88M in funding over 2 rounds. Their latest funding was raised on Jan 5, 2021 from a Series A round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jan 5, 2021 Series A $88M 1 — — Detail

Investors

Number of Lead Investors
Number of Investors
—
1
Aro Biotherapeutics is funded by 1 investors. Ionis Pharmaceuticals are the most recent investors.
Investor Name Lead Investor Funding Round
Ionis Pharmaceuticals — Series A
Cointime
İçerikler
Şirket.